Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics is asking stockholders to vote at its May 21, 2026 annual meeting on four main items: electing eight directors, ratifying Ernst & Young as auditor, approving executive pay on an advisory basis and amending the 2024 Incentive Award Plan to add more shares.
The proxy details 107,356,686 common shares outstanding as of April 9, 2026 and shows significant 2025 business progress, including revenue rising from $675.0 million in 2024 to $761.4 million and advancement of relacorilant and other cortisol modulators in oncology and metabolic indications. Executive pay is heavily equity-based, with CEO Joseph Belanoff’s 2025 package including $1.19 million salary, a matching $1.19 million bonus and options valued at about $12.9 million.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares. The sale was at a weighted average price of $40.97 per share, with individual trade prices ranging from $40.85 to $41.30.
The transactions occurred on April 7, 2026 and were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following the sale, Guyer directly holds 2,231 shares of common stock, including 224 shares underlying restricted stock awards granted on December 1, 2025 and 498 shares underlying restricted stock awards granted on March 2, 2026, which will vest in full on the one-year anniversaries of their grant dates if specified conditions are met. The option exercised was fully exercisable and was scheduled to expire on September 1, 2031.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 5,000 shares of Common Stock on April 6, 2026. The transfer was made by the James N. Wilson and Pamela D. Wilson Trust and is classified as a non-market, no‑price gift disposition.
Following the gift, the trust held 1,097,532 shares indirectly, while the James and Pamela Wilson Family Partners entity held 901,067 shares, and each of the 2025 Grantor Retained Annuity Trusts held 200,000 shares. Wilson has voting power under voting agreements but disclaims beneficial ownership beyond his pecuniary interest.
Corcept Therapeutics (CORT) notice under Rule 144 reports a sale of 20,000 common shares tied to a stock option exercise on 04/07/2026 for $817,000 via Stifel Nicolaus & Company. The filing lists prior sales by William Guyer in 02/03/2026 (20,000 shares, $817,333), 03/04/2026 (8,233 shares, $296,346), and 03/20/2026 (11,767 shares, $423,707).
Corcept Therapeutics’ Chief Executive Officer Joseph K. Belanoff reported an open-market sale of 26,198 shares of common stock at a weighted average price of $50.0735 per share. The trade was executed indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust.
The sale occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024. Following this transaction, the trust-related holdings reported for Belanoff total 2,918,326 shares of Corcept Therapeutics common stock.
The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting 0 shares of Corcept Therapeutics Inc. common stock. The amendment states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538.
The filing lists amount beneficially owned: 0 and percent of class: 0%, and is signed by Ashley Grim on 03/26/2026. The Vanguard Group indicates no single other person holds more than 5% of the reported securities.
Corcept Therapeutics reported that the U.S. Food and Drug Administration has approved its drug Lifyorli (relacorilant), used with nab-paclitaxel, to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior bevacizumab-containing regimens.
The approval is based on the pivotal ROSELLA trial in 381 patients, where Lifyorli plus nab-paclitaxel cut the risk of death by 35 percent (hazard ratio 0.65; p=0.0004) and improved median overall survival to 16.0 months, versus 11.9 months with nab-paclitaxel alone. It also reduced the risk of disease progression by 30 percent (hazard ratio 0.70; p=0.008).
Lifyorli is described as the first FDA-approved selective glucocorticoid receptor antagonist and showed a manageable safety profile, though prescribing information carries warnings for neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions and embryo-fetal toxicity, with common side effects including low blood counts, fatigue, nausea, diarrhea, rash and decreased appetite.
Corcept Therapeutics director James N. Wilson reported a bona fide gift of 4,000 shares of Common Stock. The gift was made at no stated price by the James N. Wilson and Pamela D. Wilson Trust, an entity through which he holds shares indirectly. Following this transaction, that trust holds 1,102,532 shares, with additional indirect holdings reported through a family partnership and two 2025 grantor retained annuity trusts.
Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 11,767 shares of common stock at $21.65 per share and on the same day sold 11,767 shares at a weighted average price of $36.01 per share. The sale prices ranged from $35.97 to $36.24 per share and was carried out under a Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 2,231 shares of common stock, plus 224 shares and 498 shares underlying unvested restricted stock awards that are scheduled to vest in full on the one-year anniversaries of their December 1, 2025 and March 2, 2026 grant dates, respectively, subject to specified conditions. The option exercised for 11,767 shares was fully exercisable before this transaction.